Scholarlink

<p>Central nervous system (CNS) metastases are associated with poor prognosis in patients with metastatic breast cancer (MBC). In this retrospective study, we investigated the activity of sacituzumab govitecan (SG) in 33 patients with HER2-negative MBC and CNS metastases, including active, stable/treated, and leptomeningeal disease (LMD). SG demonstrated a modest CNS objective response rate of 4/30 (13%) and median CNS-progression-free survival of 2.9 months (95%CI:2.0–4.3) in a heavily pretreated population.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Real-World outcomes with sacituzumab govitecan among breast cancer patients with central nervous system metastases

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月5日

查看全文
  • Thomas Grinda,
  • Stefania Morganti,
  • Liangge Hsu,
  • Tae-Kyung Yoo,
  • Ross J. Kusmick,
  • Ayal A. Aizer,
  • Antonio Giordano,
  • Jose P. Leone,
  • Melissa Hughes,
  • Sara M. Tolaney,
  • Nancy U. Lin,
  • Sarah L. Sammons

摘要

Central nervous system (CNS) metastases are associated with poor prognosis in patients with metastatic breast cancer (MBC). In this retrospective study, we investigated the activity of sacituzumab govitecan (SG) in 33 patients with HER2-negative MBC and CNS metastases, including active, stable/treated, and leptomeningeal disease (LMD). SG demonstrated a modest CNS objective response rate of 4/30 (13%) and median CNS-progression-free survival of 2.9 months (95%CI:2.0–4.3) in a heavily pretreated population.